 HYDERABAD, India PRINCETON, N.J.--BUSINESS WIRE--Dr. Reddys Laboratories Ltd. BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as Dr. Reddys today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric Febuxostat Tablets approved by the U.S. Food and Drug Administration USFDA. The Uloric brand and generic had U.S. sales of approximately 108 million MAT for the most recent twelve months 